Announced Date: 2024-05-16 (May 16, 2024)
Asset Name: ERAS-4001
Licensor (Seller): Medshine Discovery (China)
Licensee (Buyer): Erasca (US)
.
Asset Modality: Small Molecule
Asset Target: selective KRAS inhibitor
Potential Indication: oncology diseases
Current Stage: preclinical
.
Scope of Authority:
Erasca will be granted an exclusive license to research, develop and commercialize ERAS-4001 worldwide.
.
Payment Detail:
One-time upfront cash payment of $10.0 million,
Development, regulatory, and commercialization milestones up to $160.0 million.
Low-single digit percentage royalty.
.
Link:
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise – Erasca
.
Note:
Chinese Name of “Medshine Discovery “，明德新药
